Form 4: Gilead CFO Sells Shares Under 10b5-1 Plan

Gilead Sciences CFO Andrew D. Dickinson sold 2,500 shares of common stock for $118.53 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (GILD), reported a sale of common stock.
• The transaction involved the disposition of 2,500 shares of Gilead Sciences common stock.
• The shares were sold at a price of $118.53 per share.
• The sale occurred on August 15, 2025.
• Following this transaction, Dickinson directly beneficially owns 160,110 shares of common stock.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale can be seen negatively, the execution under a 10b5-1 plan mitigates concerns, indicating a pre-planned personal financial management decision rather than a reaction to new company-specific information.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled sale rather than a reaction to immediate negative news.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions like this Form 4 are routine disclosures in the biotechnology and pharmaceutical industries, reflecting individual executive financial planning rather than broader industry trends. The sale under a 10b5-1 plan suggests a pre-scheduled event, common for executives managing their personal portfolios.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4) and does not contain information that allows for a direct comparison of company performance or results against global benchmarks or specific comparable companies/projects. The transaction itself is a personal financial event for the executive.

Stakeholder Impact

• Shareholders: The sale by a CFO, even if pre-planned, might be viewed with slight caution by some shareholders, though the 10b5-1 plan context typically lessens negative interpretations. It does not indicate a change in company strategy or financial health.

Next Steps

• The filing does not specify any future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Recommendation

The filing is a routine Form 4 disclosing an insider sale under a pre-arranged 10b5-1 plan. This type of transaction is typically for personal financial management and does not reflect new information about the company's operational performance or future prospects. Therefore, it does not provide a basis for changing an investment thesis on Gilead Sciences, warranting a 'hold' recommendation based solely on this filing.

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Stock Sale, CFO, Andrew D. Dickinson, Rule 10b5-1 Plan, Biotechnology, Pharmaceuticals